Evidence map›Paper›PMID 38164913›Full record

ArticleLupus2024

A qualitative study of facilitators of medication adherence in systemic lupus erythematosus: Perspectives from rheumatology providers/staff and patients.

Shannon Herndon, Amy Corneli, Carrie Dombeck, Teresa Swezey, Megan Eb Clowse, Jennifer L Rogers, Lisa G Criscione-Schreiber, Rebecca E Sadun, Jayanth Doss, Amanda M Eudy and 2 more

Open access · greenAbstract read
In one paragraph

Article in Lupus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Shannon HerndonDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Amy CorneliDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Carrie DombeckDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Teresa SwezeyDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Megan Eb ClowseDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Jennifer L RogersDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Lisa G Criscione-SchreiberDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Rebecca E SadunDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Jayanth DossDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Amanda M EudyDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-3107-5545
Hayden B BosworthDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Kai SunDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-8406-2932
Duke University · US

Funding

Research Project 3U54MD012530 · NIMHD · DUKE UNIVERSITY · PI JOHNSON, KIMBERLY S. · 2017 to 2022
$8.8M
Institutional Career Development CoreKL2TR002554 · NCATS · DUKE UNIVERSITY · PI SVETKEY, LAURA P · 2018 to 2022
$8.2M
NCATS NIH HHS KL2 TR002554NIMHD NIH HHS U54 MD012530
6 · The paper itself

Abstract

objectiveSystemic lupus erythematosus (SLE) disproportionately affects patients from racial and ethnic minority groups. Medication adherence is lower among these patient populations, and nonadherence is associated with worse health outcomes. We aimed to identify factors that enable adherence to immunosuppressive medications among patients with SLE from racial and ethnic minority groups.

methodsUsing a qualitative descriptive study design, we conducted in-depth interviews with purposefully selected (1) patients with SLE from racial and ethnic minority groups who were taking immunosuppressants and (2) lupus providers and staff. We focused on adherence facilitators, asking patients to describe approaches supporting adherence and for overcoming common adherence challenges and providers and staff to describe actions they can take to foster patient adherence. We used applied thematic analysis and categorized themes using the Capability, Opportunity, Motivation, Behavior (COM-B) model.

resultsWe interviewed 12 patients (4 adherent and 8 nonadherent based on medication possession ratio) and 12 providers and staff. Although each patient described a unique set of facilitators, patients most often described social support, physical well-being, reminders, and ability to acquire medications as facilitators. Providers also commonly mentioned reminders and easy medication access as facilitators as well as patient education/communication and empowerment.

conclusionUsing an established behavioral change model, we categorized a breadth of adherence facilitators within each domain of the COM-B model while highlighting patients' individual approaches. Our findings suggest that an optimal adherence intervention may require a multi-modal and individually tailored approach including components from each behavioral domain-ensuring medication access (Capability) and utilizing reminders and social support (Opportunity), while coupled with internal motivation through improved communication and empowerment (Motivation).

Indexed as

Lupus Erythematosus, SystemicRheumatologyEthnicityHumansMedication AdherenceMinority GroupsQualitative Researchbehaviorhealthcare disparitiesimmunosuppressive agentsmedication adherencequalitative researchSystemic lupus erythematosus

Identifiers

PMID38164913
PMCPMC10922388
OpenAlexW4390500141

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.